Timothy Grass Allergy: The Gold Standard That Defines All Grass Treatment

Timothy grass (Phleum pratense) became the reference standard because it is the most completely characterized grass allergen species, with 10 WHO/IUIS-recognized allergens (Phl p 1 through Phl p 13) mapped to specific protein families and sensitization rates. Phl p 1 (beta-expansin) and Phl p 5 (ribonuclease-like) together detect more than 95% of grass-allergic patients' IgE, making them the most efficient diagnostic combination available for any pollen allergen. All other Pooideae grasses share these allergens with approximately 95% sequence identity, so testing to timothy is clinically equivalent to testing to ryegrass, fescue, bluegrass, orchard, and sweet vernal grass simultaneously. This efficiency made timothy the natural choice as the single reference species for diagnosis and the sole allergen in Grastek.

Grastek treats all Pooideae (cool-season, sweet grass) allergies through cross-reactivity — this includes timothy, perennial ryegrass, fescue, Kentucky bluegrass, orchard grass, and sweet vernal grass. However, Grastek does NOT treat bermuda grass (Cynodon dactylon, subfamily Chloridoideae) or bahia grass (Paspalum notatum, subfamily Panicoideae). These warm-season grasses lack the Group 5 allergens that form the basis for Pooideae cross-reactivity. Patients in the Sun Belt who react to grass during an extended season — particularly spring-through-fall — may have bermuda sensitization that Grastek leaves entirely untreated. Component testing for Cyn d 1 (bermuda) alongside Phl p 5 (timothy/Pooideae) distinguishes which grasses are driving symptoms and determines whether a separate bermuda extract is required.

Phl p 5 is a ribonuclease-like protein (Group 5 allergen) found exclusively in Pooideae grasses — it is completely absent from bermuda (Chloridoideae) and bahia (Panicoideae). It is present in approximately 65 to 90% of grass-sensitized patients and serves as the diagnostic biomarker that distinguishes Pooideae from warm-season grass sensitization. A positive Phl p 5 test result carries two critical clinical implications: first, the patient is sensitized to all Pooideae grasses (timothy, ryegrass, fescue, bluegrass, orchard, sweet vernal) through the same IgE; second, a single timothy-based immunotherapy (Grastek, SCIT, or SLIT drops) will effectively treat the entire grass sensitization. Negative Phl p 5 with positive Phl p 1 warrants bermuda testing (Cyn d 1), as it suggests a different sensitization profile.

Timothy grass allergy rarely resolves spontaneously in adults. Unlike food allergies in children, which frequently outgrow their sensitization by school age, IgE-mediated inhalant pollen allergies tend to persist and often worsen with continued seasonal re-exposure. Annual pollen seasons sustain and can amplify specific IgE production, progressively lowering the threshold for symptom onset. The probability of natural resolution in adults is estimated at under 15% over any given 5-year period without intervention. Disease-modifying immunotherapy is the only evidence-based treatment that systematically reduces specific IgE and shifts the immune response toward tolerance, creating the conditions for sustained symptom reduction that antihistamines and nasal sprays cannot produce.

Probably yes, if you live in the northern US. Kentucky bluegrass is the most planted residential lawn grass in the northern and mid-Atlantic United States, and it is a Pooideae grass that shares approximately 95% cross-reactivity with timothy via Group 1 and Group 5 allergens. Fescue is the dominant lawn grass in the transition zone — also Pooideae, also cross-reactive. If a positive Phl p 5 confirms your sensitization, your IgE is reactive to all Pooideae grasses, including whatever species your lawn contains. The practical implication: your allergen is in your backyard. The good news is that the same timothy-based immunotherapy that addresses pasture grass exposure also addresses your lawn grass — a single treatment covers both.

Timothy grass and bermuda grass produce allergies through immunologically distinct mechanisms that require completely different treatments. Timothy (Pooideae) carries Group 5 allergens (Phl p 5) that bermuda completely lacks. Bermuda's major allergen Cyn d 1 has unique epitopes not recognized by timothy-specific IgE. The clinical consequence is that standard grass immunotherapy using timothy extract — including Grastek and Oralair — will not treat bermuda sensitization at all. A patient living in Phoenix who takes Grastek may be entirely unprotected against their primary grass exposure. Component testing (Phl p 5 vs. Cyn d 1) is the only way to determine which type of grass allergy is driving symptoms, and the results determine whether a single or multi-extract immunotherapy is needed.

Yes, timothy grass sensitization is a recognized cause of allergic asthma, and the two conditions frequently coexist. Roughly a third to two-fifths of patients with timothy-driven allergic rhinitis have measurable bronchial hyperreactivity, and a significant proportion meet formal asthma criteria. The mechanism is the same eosinophilic inflammation driven by Th2 immune activation — the same IgE that produces mast cell degranulation in the nasal mucosa also drives eosinophilic infiltration in the bronchial mucosa, increasing airway reactivity to cold air, exercise, and respiratory infections. Grastek pivotal trials demonstrated not only nasal symptom reduction but also reduced bronchoprovocation reactivity over three seasons, confirming that disease-modifying immunotherapy addresses both the upper and lower airway components of the allergic response.

Optimally, start disease-modifying immunotherapy the winter before grass season — January or February. Grastek requires at least 12 weeks of pre-season dosing to achieve full protection, meaning a January start ensures full benefit before June peak. Oralair requires 4 months of pre-season initiation, pointing to a December or January start. For SLIT drops, initiation can begin year-round, with pre-seasonal starts preferred. For seasonal medications, intranasal corticosteroids should begin in late April, two weeks before expected season onset, so that full mucosal protection is established before the June pollen peak. Patients who start medications reactively in mid-June, when symptoms are already severe, are consistently less well-controlled than those who begin pre-emptively.

Most grass-allergic patients do not need to avoid foods, but a subset experiences oral allergy syndrome from grass pollen profilin cross-reactivity (Phl p 12). Cross-reactive foods include raw tomato, watermelon, cantaloupe, peach, celery, kiwi, orange, banana, and peanut. Symptoms are typically mild — oral tingling and itching beginning within minutes — and resolve spontaneously. Cooking or processing these foods destroys the heat-labile profilin proteins, making them safe in cooked forms. Systemic reactions from this cross-reactivity are uncommon. If you notice oral symptoms with any of these foods, report the pattern to your allergist for pathway characterization rather than eliminating the foods preemptively.

Genetic predisposition plays a substantial role in grass pollen sensitization. First-degree relatives of grass-allergic patients have approximately two to three times the sensitization rate of the general population, driven by inherited Th2 immune polarization tendencies. Genome-wide association studies have identified multiple loci associated with allergic rhinitis and grass sensitization, including genes involved in epithelial barrier function (EMSY, HLA region), Th2 cytokine signaling (IL-13, IL-33, TSLP), and IgE regulation (FCER1A). However, genetics alone is not deterministic — environmental factors including pollen load, air pollution, microbial diversity, and early childhood exposures all shape whether a genetically susceptible individual becomes clinically sensitized. The combination of genetic risk and repeated high-intensity pollen exposure, particularly in hay-crop growing regions, produces the highest sensitization rates.

Grastek is a prescription sublingual immunotherapy tablet containing standardized timothy grass pollen allergen, taken daily under the tongue to treat grass pollen allergic rhinitis. The most common side effects are local — mouth or throat irritation, itching, or swelling — particularly with the first few doses, and these typically lessen with continued use. Because of a rare risk of severe allergic reaction, the first dose is taken under medical supervision, and your allergist will advise on when to start it relative to grass season.

No — timothy (Phleum pratense) is a grass, not a tree, despite names like 'timothy hay' sometimes causing confusion. It's a cool-season Pooideae grass commonly grown for hay and found in lawns and pastures, and its pollen is one of the most significant causes of seasonal grass allergy.